Mark Newcomer Sells 61,000 Shares of Paysign, Inc. (NASDAQ:PAYS) Stock

Paysign, Inc. (NASDAQ:PAYS) CEO Mark Newcomer sold 61,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $2.89, for a total transaction of $176,290.00. Following the completion of the transaction, the chief executive officer now directly owns 9,075,886 shares of the company’s stock, valued at $26,229,310.54. This trade represents a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mark Newcomer also recently made the following trade(s):

• On Thursday, January 23rd, Mark Newcomer sold 12,000 shares of Paysign stock. The stock was sold at an average price of $2.85, for a total value of $34,200.00.
• On Monday, December 9th, Mark Newcomer sold 41,000 shares of Paysign stock. The stock was sold at an average price of $3.31, for a total value of $135,710.00.
• On Wednesday, November 20th, Mark Newcomer sold 25,000 shares of Paysign stock. The shares were sold at an average price of $3.27, for a total value of $81,750.00.
• On Monday, November 18th, Mark Newcomer sold 40,000 shares of Paysign stock. The stock was sold at an average price of $3.24, for a total value of $129,600.00.

Paysign Stock Up 1.4 %

NASDAQ PAYS opened at $2.90 on Friday. Paysign, Inc. has a 12-month low of $2.70 and a 12-month high of $5.59. The firm’s 50 day moving average is $3.16 and its 200-day moving average is $3.91. The company has a market capitalization of $155.30 million, a PE ratio of 19.33 and a beta of 0.95.

Paysign (NASDAQ:PAYS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.01 by $0.02. The firm had revenue of $15.26 million for the quarter, compared to analysts’ expectations of $14.96 million. Paysign had a net margin of 14.28% and a return on equity of 30.64%. During the same period in the previous year, the firm posted $0.02 EPS. As a group, sell-side analysts expect that Paysign, Inc. will post 0.21 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Joule Financial LLC acquired a new stake in shares of Paysign in the 3rd quarter valued at approximately $1,478,000. Renaissance Technologies LLC lifted its stake in Paysign by 25.0% in the second quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company’s stock valued at $6,484,000 after acquiring an additional 301,000 shares during the last quarter. Royce & Associates LP acquired a new stake in Paysign in the third quarter valued at $814,000. Sanctuary Advisors LLC bought a new position in shares of Paysign in the 2nd quarter valued at about $512,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Paysign by 51.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 116,779 shares of the company’s stock worth $502,000 after purchasing an additional 39,710 shares during the last quarter. 25.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PAYS has been the subject of several research analyst reports. Lake Street Capital started coverage on shares of Paysign in a report on Friday, December 20th. They issued a “buy” rating and a $6.00 price target for the company. Barrington Research reiterated an “outperform” rating and set a $7.00 target price on shares of Paysign in a report on Monday, November 4th.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.